ReviewWorld journal of clinical cases2021
Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy.
Review in World journal of clinical cases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Research Progress in Pharmacological Targeted Therapy for Myasthenia Gravis.Journal of inflammation research · 2026Review
- Synchronous triple-negative breast cancer, rectal adenocarcinoma, and chemotherapy-induced hepatitis B virus reactivation: a case report and review of the literature.Journal of medical case reports · 2025Review
- Juvenile Dermatomyositis and Hepatitis B Viral Infection.European journal of case reports in internal medicine · 2025Article
- Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy.Current oncology (Toronto, Ont.) · 2024Article
- Article
- Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation.Annals of hematology · 2023Article
- Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.World journal of hepatology · 2023Review
- Entecavir: A Review and Considerations for Its Application in Oncology.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Case report: An occult hepatitis B virus infection reactivation in an HIV/HCV coinfected patient during an immune reconstitution inflammatory syndrome.Frontiers in cellular and infection microbiology · 2023Article
- Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies.Journal of clinical and translational hepatology · 2022Review
- Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19.Pathogens (Basel, Switzerland) · 2022Review
- Article
- Hepatitis B functional cure and immune response.Frontiers in immunology · 2022Review
- Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) reactivation can lead to severe acute hepatic failure and death in patients with HBV infection. HBV reactivation (HBVr) most commonly develops in patients undergoing cancer chemotherapy, especially B cell-depleting agent therapy such as rituximab and ofatumumab for hematological or solid organ malignancies and that receiving hematopoietic stem cell transplantation without antiviral prophylaxis. In addition, the potential consequences of HBVr is particularly a concern when patients are exposed to either immunosuppressive or biologic therapies for the management of rheumatologic diseases, inflammatory bowel disease and dermatologic diseases. Thus, screening with HBV serological markers and prophylactic or pre-emptive antiviral treatment with nucleos(t)ide analogues should be considered in these patients to diminish the risk of HBVr. This review discusses the clinical manifestation, prognosis and management of HBVr, risk stratifications of cancer chemotherapy and immunosuppressive therapy and international guideline recommendations for the prevention of HBVr in patients with HBV infection and resolved hepatitis B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.